Kamada Ltd. (KMDA)
USD 5.76
(-1.37%)
USD 5.76
(-1.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 351.96 Million USD | 9.18% |
| 2022 | 322.37 Million USD | 1.16% |
| 2021 | 318.66 Million USD | 51.27% |
| 2020 | 210.66 Million USD | 21.21% |
| 2019 | 173.79 Million USD | 25.83% |
| 2018 | 138.11 Million USD | 13.11% |
| 2017 | 122.11 Million USD | 22.48% |
| 2016 | 99.69 Million USD | -2.25% |
| 2015 | 101.99 Million USD | -14.74% |
| 2014 | 119.61 Million USD | -14.18% |
| 2013 | 139.37 Million USD | 56.41% |
| 2012 | 89.11 Million USD | 4.29% |
| 2011 | 85.44 Million USD | -6.63% |
| 2010 | 91.52 Million USD | 45.48% |
| 2009 | 62.91 Million USD | 49.57% |
| 2008 | 42.06 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 340.05 Million USD | -3.38% |
| 2024 Q2 | 349.92 Million USD | 2.9% |
| 2023 Q2 | 314.38 Million USD | -0.76% |
| 2023 FY | 351.96 Million USD | 9.18% |
| 2023 Q4 | 351.96 Million USD | 4.42% |
| 2023 Q1 | 316.79 Million USD | -1.73% |
| 2023 Q3 | 337.05 Million USD | 7.21% |
| 2022 Q3 | 319.63 Million USD | 5.1% |
| 2022 Q1 | 303.09 Million USD | -4.89% |
| 2022 Q2 | 304.13 Million USD | 0.34% |
| 2022 FY | 322.37 Million USD | 1.16% |
| 2022 Q4 | 322.37 Million USD | 0.86% |
| 2021 Q3 | 216.52 Million USD | 0.08% |
| 2021 Q1 | 210.52 Million USD | -0.07% |
| 2021 FY | 318.66 Million USD | 51.27% |
| 2021 Q2 | 216.35 Million USD | 2.77% |
| 2021 Q4 | 318.66 Million USD | 47.17% |
| 2020 Q3 | 206.34 Million USD | 0.12% |
| 2020 Q2 | 206.09 Million USD | 4.72% |
| 2020 Q1 | 196.79 Million USD | 13.23% |
| 2020 Q4 | 210.66 Million USD | 2.09% |
| 2020 FY | 210.66 Million USD | 21.21% |
| 2019 FY | 173.79 Million USD | 25.83% |
| 2019 Q1 | 145.09 Million USD | 5.05% |
| 2019 Q2 | 156.48 Million USD | 7.85% |
| 2019 Q3 | 156.5 Million USD | 0.01% |
| 2019 Q4 | 173.79 Million USD | 11.05% |
| 2018 Q4 | 138.11 Million USD | 19.97% |
| 2018 FY | 138.11 Million USD | 13.11% |
| 2018 Q3 | 115.12 Million USD | -6.93% |
| 2018 Q2 | 123.69 Million USD | 2.62% |
| 2018 Q1 | 120.53 Million USD | -1.29% |
| 2017 Q3 | 111.98 Million USD | 11.77% |
| 2017 Q2 | 100.19 Million USD | 7.59% |
| 2017 Q1 | 93.12 Million USD | -6.59% |
| 2017 FY | 122.11 Million USD | 22.48% |
| 2017 Q4 | 122.11 Million USD | 9.04% |
| 2016 Q2 | 98.57 Million USD | -7.57% |
| 2016 Q3 | 94.59 Million USD | -4.03% |
| 2016 Q4 | 99.69 Million USD | 5.39% |
| 2016 Q1 | 106.64 Million USD | 4.56% |
| 2016 FY | 99.69 Million USD | -2.25% |
| 2015 Q4 | 101.99 Million USD | -5.94% |
| 2015 Q1 | 110.58 Million USD | -7.55% |
| 2015 Q2 | 110.76 Million USD | 0.15% |
| 2015 FY | 101.99 Million USD | -14.74% |
| 2015 Q3 | 108.43 Million USD | -2.1% |
| 2014 Q3 | 126.23 Million USD | -3.56% |
| 2014 Q1 | 138.26 Million USD | -0.8% |
| 2014 Q2 | 130.89 Million USD | -5.32% |
| 2014 FY | 119.61 Million USD | -14.18% |
| 2014 Q4 | 119.61 Million USD | -5.24% |
| 2013 FY | 139.37 Million USD | 56.41% |
| 2013 Q3 | 139.32 Million USD | -0.87% |
| 2013 Q2 | 140.54 Million USD | 58.72% |
| 2013 Q1 | 88.55 Million USD | -0.63% |
| 2013 Q4 | 139.37 Million USD | 0.04% |
| 2012 FY | 89.11 Million USD | 4.29% |
| 2012 Q3 | 86.17 Million USD | 0.0% |
| 2012 Q4 | 89.11 Million USD | 3.42% |
| 2011 FY | 85.44 Million USD | -6.63% |
| 2010 FY | 91.52 Million USD | 45.48% |
| 2009 FY | 62.91 Million USD | 49.57% |
| 2008 FY | 42.06 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -358.002% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 61.083% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -512.995% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 77.644% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1187.052% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1187.052% |
| SCYNEXIS, Inc. | 128.41 Million USD | -174.094% |
| Safety Shot Inc | 12.7 Million USD | -2669.413% |
| Alpha Teknova, Inc. | 128.58 Million USD | -173.721% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 69.215% |
| Bright Green Corporation | 17.4 Million USD | -1922.46% |
| Dynavax Technologies Corporation | 997.09 Million USD | 64.701% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -71.028% |
| Cosmos Health Inc. | 66.29 Million USD | -430.91% |
| PainReform Ltd. | 9.93 Million USD | -3444.509% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1421.896% |
| Embecta Corp. | 1.21 Billion USD | 71.017% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 51.672% |
| Procaps Group, S.A. | 460.18 Million USD | 23.516% |
| Theratechnologies Inc. | 77.76 Million USD | -352.584% |
| Harrow Health, Inc. | 311.75 Million USD | -12.899% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -2263.323% |
| Biofrontera Inc. | 27.93 Million USD | -1160.095% |
| DURECT Corporation | 45.18 Million USD | -678.884% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 75.019% |
| Cronos Group Inc. | 1.13 Billion USD | 68.969% |
| OptiNose, Inc. | 107.72 Million USD | -226.718% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 25.283% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -529.09% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1427.173% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 23.489% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -2853.218% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -330.407% |
| Radius Health, Inc. | 1.71 Billion USD | 79.488% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -560.517% |
| ProPhase Labs, Inc. | 91.92 Million USD | -282.88% |
| Phibro Animal Health Corporation | 982.18 Million USD | 64.165% |
| Procaps Group S.A. | 460.18 Million USD | 23.516% |
| Alvotech | 950.09 Million USD | 62.954% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -712.694% |
| Viatris Inc. | 47.68 Billion USD | 99.262% |
| Rockwell Medical, Inc. | 52.17 Million USD | -574.62% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -198.039% |
| SIGA Technologies, Inc. | 254.83 Million USD | -38.116% |
| Tilray Brands, Inc. | 4.33 Billion USD | 91.881% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -28.596% |
| Shineco, Inc. | 84.17 Million USD | -318.119% |
| PetIQ, Inc. | 868.22 Million USD | 59.461% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -4071.142% |
| Incannex Healthcare Limited | 17.04 Million USD | -1964.702% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 89.175% |
| Alimera Sciences, Inc. | 153.52 Million USD | -129.26% |
| Silver Spike Investment Corp. | 88.57 Million USD | -297.363% |
| Assertio Holdings, Inc. | 286.41 Million USD | -22.886% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -5813.732% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -941.46% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -1026.556% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2556.869% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -34.789% |
| Hempacco Co., Inc. | 18.04 Million USD | -1850.719% |
| Talphera, Inc. | 20.39 Million USD | -1625.765% |
| Alvotech | 950.09 Million USD | 62.954% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 13.342% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 78.683% |
| Currenc Group, Inc. | 141.49 Million USD | -148.759% |
| Indivior PLC | 1.95 Billion USD | 81.962% |
| Evoke Pharma, Inc. | 7.06 Million USD | -4879.38% |
| Flora Growth Corp. | 23.62 Million USD | -1389.756% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2556.869% |
| Evolus, Inc. | 188.99 Million USD | -86.229% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 72.497% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 76.736% |
| Akanda Corp. | 8.83 Million USD | -3881.561% |